Publicaciones en colaboración con investigadores/as de University College London (33)

2024

  1. Psychopharmacology in children and adolescents: unmet needs and opportunities

    The Lancet Psychiatry, Vol. 11, Núm. 2, pp. 143-154

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: Results from the EU-GEI case-control study

    Psychological Medicine, Vol. 53, Núm. 15, pp. 7375-7384

  3. Development and Validation of Predictive Model for a Diagnosis of First Episode Psychosis Using the Multinational EU-GEI Case-control Study and Modern Statistical Learning Methods

    Schizophrenia Bulletin Open, Vol. 4, Núm. 1

  4. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  5. Exploring the mediation of DNA methylation across the epigenome between childhood adversity and First Episode of Psychosis—findings from the EU-GEI study

    Molecular Psychiatry, Vol. 28, Núm. 5, pp. 2095-2106

  6. First-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data

    Schizophrenia bulletin, Vol. 49, Núm. 1, pp. 218-227

  7. Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations

    Nature genetics, Vol. 55, Núm. 3, pp. 369-376

  8. Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis: The EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 5, pp. 1970-1978

  9. The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study

    Psychological medicine, Vol. 53, Núm. 15, pp. 7418-7427

  10. The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications

    Neuroscience and Biobehavioral Reviews, Vol. 149

  11. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

  12. Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; The EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 8, pp. 3396-3405

2022

  1. Childhood Maltreatment, Educational Attainment, and IQ: Findings from a Multicentric Case-control Study of First-episode Psychosis (EU-GEI)

    Schizophrenia Bulletin, Vol. 48, Núm. 3, pp. 575-589

  2. Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case-Control Study

    Schizophrenia bulletin, Vol. 48, Núm. 5, pp. 1104-1114

  3. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

  4. Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a six-country case-control study

    Psychological Medicine, Vol. 52, Núm. 15, pp. 3668-3676

2021

  1. Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: The EU-GEI case-control study

    Psychological Medicine, Vol. 51, Núm. 8, pp. 1329-1337

  2. Duration of Untreated Psychosis in First-Episode Psychosis is not Associated with Common Genetic Variants for Major Psychiatric Conditions: Results from the Multi-Center EU-GEI Study

    Schizophrenia Bulletin, Vol. 47, Núm. 6, pp. 1653-1662

  3. Jumping to conclusions, general intelligence, and psychosis liability: Findings from the multi-centre EU-GEI case-control study

    Psychological Medicine, Vol. 51, Núm. 4, pp. 623-633